Magnesium Meta-Analysis Stress Research

Last updated: October 4, 2026 - Reviewed by Verdant Wellness Editorial Team

---

Table of Contents

1. Why Meta-Analysis Evidence Matters for Magnesium and Stress
2. What the Magnesium Systematic Review Literature Covers
3. Key Findings From Magnesium Anxiety Meta-Analysis Studies
4. Magnesium Cortisol Review: What the Biomarker Data Shows
5. Magnesium Anxiety Pooled Data: Dose, Duration, and Effect Sizes
6. Magnesium With Vitamin B6: Does the Combination Change the Evidence?
7. Magnesium Mental Health Review: Depression, Sleep, and Beyond
8. Magnesium Evidence Analysis: Limitations and Research Gaps
9. Upcoming Magnesium Evidence Review: What the 2026 PROSPERO Protocol Plans to Answer
10. Practical Takeaways From the Magnesium Clinical Evidence Synthesis
11. Frequently Asked Questions

---

Introduction

If you have spent any time researching natural approaches to stress and anxiety, you have almost certainly encountered claims about magnesium. Supplement labels describe it as "nature's relaxation mineral." Wellness blogs promise it will calm your nervous system overnight. But what does the clinical research actually say when you pool the best available randomized controlled trials together into a formal magnesium meta-analysis or stress research synthesis?

That is exactly what this article examines. Rather than cherry-picking a single promising study, this post walks you through the magnesium stress meta literature as it currently stands — including a landmark 2025 systematic review and meta-analysis, a 2021 randomized trial with secondary analysis, and a 2026 PROSPERO-registered protocol that signals where the field is heading next. We will look at effect sizes, biomarker data, dose-response relationships, combination strategies with vitamin B6, and the important methodological caveats every reader deserves to understand before drawing conclusions.

The goal is not to sell you on magnesium or dismiss it. The goal is to give you the clearest, most honest synthesis of what the magnesium clinical review literature actually supports — and what it does not.

---

Individual studies on any supplement can be misleading. A single trial might show impressive results simply because its sample was small, its outcome measures were imprecise, or its participants happened to be severely deficient in magnesium at baseline. Conversely, a single negative trial might reflect a poorly chosen dose or the wrong form of magnesium rather than a genuine absence of effect.

This is precisely why the magnesium evidence review field relies increasingly on systematic reviews and meta-analyses. A well-conducted systematic review pre-registers its search strategy, defines inclusion and exclusion criteria before looking at the data, and attempts to locate every relevant published and unpublished trial. A meta-analysis then statistically pools effect sizes across those trials, giving a weighted estimate that is more reliable than any single data point.

When we talk about magnesium clinical evidence synthesis, we are talking about this rigorous, hierarchical approach to evidence. The conclusions that emerge from a properly conducted magnesium evidence analysis carry far more weight than any individual randomized controlled trial — and far more weight than observational studies, case reports, or the kind of testimonial evidence that fills consumer health pages.

With that framework in mind, here is what the current body of magnesium systematic review and meta-analysis research actually shows.

---

What the Magnesium Systematic Review Literature Covers

The magnesium systematic review literature spans multiple outcome domains. Researchers have pooled data on:

• Psychological stress scores measured by validated instruments such as the Depression Anxiety Stress Scales (DASS-21 and DASS-42), the Perceived Stress Scale (PSS), and the State-Trait Anxiety Inventory (STAI)
• Biochemical stress markers including cortisol, C-reactive protein (CRP), nitric oxide (NO), total antioxidant capacity (TAC), malondialdehyde (MDA), and glutathione (GSH)
• Mood and depression outcomes often measured alongside anxiety and stress because the three domains overlap substantially in clinical populations
• Sleep quality as a secondary outcome in several anxiety and stress trials

It is important to understand that these outcome domains are not interchangeable. A study showing that magnesium lowers a self-reported stress score is not the same as a study showing it lowers cortisol. A magnesium anxiety meta-analysis that pools DASS scores may reach a different conclusion than one that pools serum cortisol measurements. The magnesium evidence analysis literature is therefore best understood as a collection of related but distinct bodies of evidence rather than one unified finding.

The most comprehensive recent piece of magnesium clinical review work is a 2025 systematic review and meta-analysis published in a peer-reviewed journal, which examined 28 relevant articles covering the period from 2000 through 2025. This review focused specifically on magnesium supplementation and oxidative stress and inflammation biomarkers. Its conclusions, which we examine in detail below, are more nuanced than many popular summaries suggest.

---

The 2025 Systematic Review and Meta-Analysis

The most current and methodologically rigorous piece of the magnesium anxiety meta-analysis literature is the 2025 systematic review and meta-analysis that synthesized 28 studies published between 2000 and 2025. A few key findings deserve careful attention.

What the 2025 review found — CRP reduction: The review identified a statistically significant reduction in C-reactive protein (CRP) following magnesium supplementation. CRP is a well-validated inflammatory biomarker that tends to be elevated in people experiencing chronic psychological stress, burnout, and anxiety disorders. The finding that magnesium supplementation produced a consistent, significant CRP reduction across pooled studies is meaningful, because chronic low-grade inflammation is increasingly understood as both a consequence of stress and a contributor to anxiety and depressive symptoms.

What the 2025 review found — oxidative stress biomarkers: The same review found that effects on other oxidative stress biomarkers — specifically nitric oxide (NO), total antioxidant capacity (TAC), malondialdehyde (MDA), and glutathione (GSH) — were inconclusive. The data across studies were too heterogeneous to produce reliable pooled estimates for these outcomes. This does not mean magnesium has no effect on oxidative stress pathways; it means the current evidence is insufficient to draw firm conclusions.

What this means for the magnesium anxiety meta-analysis picture: The 2025 review tells us that magnesium supplementation likely exerts anti-inflammatory effects measurable through CRP, but that its broader antioxidant profile at standard supplementation doses remains uncertain. For people interested in the stress-anxiety dimension specifically, the CRP finding is encouraging because neuroinflammatory models of anxiety increasingly implicate elevated inflammatory markers in symptom generation and maintenance.

The 2021 Randomized Trial and Secondary Analysis

A 2021 randomized controlled trial with secondary analysis examined magnesium supplementation in stressed but otherwise healthy adults. Participants received either magnesium alone or magnesium combined with vitamin B6, and outcomes were measured using the DASS-42 — a well-validated, 42-item questionnaire that generates separate subscale scores for depression, anxiety, and stress.

The results were clinically notable. By the end of eight weeks, both the magnesium-alone group and the magnesium-plus-B6 group showed improvements in DASS-42 depression and anxiety subscale scores to normal or near-normal ranges. Critically, the secondary analysis found that the greatest magnitude of change occurred in the first four weeks of supplementation, suggesting that whatever mechanism drives the improvement activates relatively quickly and then stabilizes rather than showing a slow, linear accumulation.

This finding is relevant for the magnesium evidence review literature because it offers a plausible timeline for expected benefit: four weeks for substantial improvement, eight weeks for near-normalization in a stressed but otherwise healthy population.

---

Magnesium Cortisol Review: What the Biomarker Data Shows

The magnesium cortisol review literature is thinner and more inconsistent than the self-reported outcome literature. Cortisol is the body's primary stress hormone, produced by the adrenal glands in response to hypothalamic-pituitary-adrenal (HPA) axis activation. The theoretical basis for expecting magnesium to modulate cortisol is reasonable: magnesium acts as a calcium antagonist in many cellular systems, and calcium signaling plays a role in cortisol secretion. Additionally, magnesium deficiency has been associated with HPA axis hyperreactivity in animal models.

However, translating that mechanistic rationale into consistent human trial findings has proven difficult. The challenges in the magnesium cortisol review literature include:

1. Measurement variability: Cortisol fluctuates substantially across the day (diurnal rhythm), in response to meal timing, exercise, sleep quality, and even the stress of having a blood draw. Different studies measure cortisol at different time points, making pooled estimates noisy.

1. Population heterogeneity: The effect of magnesium on cortisol may depend heavily on baseline magnesium status. Participants who are already magnesium-replete are unlikely to show changes; those with suboptimal magnesium intake may show meaningful HPA axis normalization.

1. Supplementation dose and form: The magnesium evidence analysis literature covers a wide range of doses (from roughly 150 mg to 600 mg elemental magnesium per day) and multiple forms (magnesium oxide, citrate, glycinate, threonate, lactate, and others), each with different bioavailability profiles.

The 2025 systematic review and meta-analysis mentioned above focused primarily on oxidative stress and inflammatory biomarkers rather than cortisol specifically, which means the most current comprehensive magnesium cortisol review remains an evidence gap that the field has not fully addressed. The 2026 PROSPERO-registered protocol, discussed later in this article, does plan to include cortisol-related physiological outcomes as part of its broader assessment.

For now, the most defensible summary of the magnesium cortisol review literature is: there is a plausible mechanistic rationale, preliminary evidence of HPA axis modulation in deficient populations, and a need for better-powered, better-controlled trials before firm conclusions can be drawn.

---

Magnesium Anxiety Pooled Data: Dose, Duration, and Effect Sizes

When we look specifically at the magnesium anxiety pooled data from multiple sources, three practical variables emerge as critical: dose, duration, and baseline status.

Dose

The most commonly used dose in stress and anxiety trials is approximately 300 mg of elemental magnesium per day. A 2020 review noted that daily supplementation with 300 mg magnesium — with or without 30 mg vitamin B6 — produced stress-relief benefits, particularly in participants with severe baseline stress. This dose is broadly consistent with the research showing that the recommended dietary allowance (RDA) for magnesium sits around 310–420 mg per day for adults, and that a meaningful proportion of Western populations fail to reach this through diet alone.

Higher doses (400 mg to 600 mg) have been used in some trials without substantially greater benefit, and at doses above 350 mg from supplemental sources, the risk of gastrointestinal side effects — primarily loose stools and diarrhea — begins to increase for some individuals. The magnesium evidence analysis literature does not currently support the assumption that higher is better.

Duration

The magnesium stress meta literature consistently suggests that meaningful psychological benefits require at least four weeks of daily supplementation. The 2021 randomized trial found that the greatest change in DASS-42 scores occurred in the first four weeks, with stabilization at or near normal levels by week eight. This is a practically important finding: people who try magnesium for one week and notice nothing should not necessarily conclude it is ineffective.

Effect Sizes and DASS Score Reductions

The 2020 review reported DASS score reductions of up to 45% from baseline in participants with severe initial stress scores who received 300 mg magnesium with or without vitamin B6. This is a substantial effect size, though it is important to note that people with severe baseline scores have more room to improve — regression to the mean is always a consideration in these analyses.

The same 2020 review found that magnesium intake was negatively correlated with stress, depression, and total DASS scores in the data examined. This means higher magnesium intake was associated with lower stress and depression scores — a finding consistent across both supplementation trials and dietary intake studies, though correlational data from dietary studies cannot establish causation.

Form of Magnesium

The magnesium anxiety pooled data literature is frustratingly heterogeneous when it comes to form. Different studies use different salt forms of magnesium, and bioavailability varies considerably. Magnesium oxide, for example, has lower bioavailability than magnesium citrate, glycinate, or threonate. Most meta-analyses have not been able to conduct meaningful subgroup analyses by form because of the limited number of trials using each specific form. This remains a significant gap in the magnesium clinical review literature.

---

Magnesium With Vitamin B6: Does the Combination Change the Evidence?

Several trials within the magnesium clinical evidence synthesis literature have tested magnesium in combination with vitamin B6, and the results raise an interesting question: does B6 augment the stress-reducing effects of magnesium, or are the benefits primarily driven by magnesium alone?

What the 2021 Trial Found

The 2021 randomized trial with secondary analysis compared magnesium alone versus magnesium plus vitamin B6 in stressed healthy adults. Both groups improved substantially on DASS-42 depression and anxiety scores by week eight. The secondary analysis found a specific subgroup effect: participants who had the most severe baseline stress scores showed a significantly greater improvement with the combination than with magnesium alone.

This is a nuanced but important finding. It suggests that for people with moderate or mild stress, magnesium alone may be sufficient to produce meaningful improvement. For people with severe stress at baseline, adding vitamin B6 appears to provide additional benefit beyond what magnesium alone achieves.

The Biological Rationale

The theoretical basis for the combination is reasonably well grounded. Vitamin B6 (pyridoxine) is a cofactor in the synthesis of several neurotransmitters involved in stress regulation, including serotonin, dopamine, and gamma-aminobutyric acid (GABA). Magnesium, meanwhile, modulates NMDA receptor activity, influences GABA receptor function, and regulates calcium channel conductance in neurons. The two nutrients may operate through partially overlapping but distinct pathways, which would explain why their combination could produce additive effects in high-stress individuals.

Caveats

The magnesium evidence review literature on the combination is still limited. Most combination trials use 300 mg magnesium with 30 mg vitamin B6, and there are relatively few trials that directly compare this combination against equivalent doses of each nutrient alone. The magnesium anxiety meta-analysis literature does not yet have enough combination-arm data to produce reliable pooled estimates specifically for the combination versus magnesium monotherapy.

---

Magnesium Mental Health Review: Depression, Sleep, and Beyond

The magnesium mental health review literature extends beyond stress and anxiety into related domains that frequently co-occur with chronic stress. Understanding these adjacent evidence streams helps complete the picture.

Magnesium and Depression

The 2021 randomized trial measured both anxiety and depression subscales of the DASS-42 and found improvements in both domains. The 2020 review similarly reported that magnesium intake was negatively correlated not just with stress but with depression scores in the reviewed data. This overlap is not surprising — depression, anxiety, and chronic stress share overlapping neurobiological substrates including HPA axis dysregulation, reduced GABAergic tone, and elevated inflammatory markers.

Several earlier systematic reviews (prior to 2020) on magnesium and depression found preliminary positive signals but were limited by small sample sizes, short durations, and methodological heterogeneity across trials. The magnesium mental health review field has gradually improved in methodological rigor, but depression specifically remains an area where more well-powered trials are needed.

Magnesium and Sleep

Sleep disruption and stress form a bidirectional vicious cycle: stress impairs sleep quality, and poor sleep amplifies stress reactivity. Magnesium's role in sleep regulation has a plausible physiological basis — it modulates NMDA receptors and GABA-A receptors, both of which are centrally involved in sleep architecture and transition to deeper sleep stages.

However, the magnesium evidence analysis literature on sleep is less robust than the stress and anxiety evidence stream. Most stress trials that include sleep as a secondary outcome report improvements in subjective sleep quality, but few trials are designed primarily to test sleep outcomes with adequate power. The magnesium clinical review community generally treats sleep as a likely co-benefit of effective stress reduction rather than an independently well-established primary effect at standard doses.

Broader Mental Health Applications

The magnesium mental health review literature also includes preliminary work on magnesium in post-traumatic stress disorder (PTSD), premenstrual syndrome (PMS)-related mood symptoms, and perimenopause-associated anxiety. These represent emerging areas of interest rather than established evidence, and most rely on small trials or observational data.

The overarching pattern across the magnesium mental health review literature is one of consistent, if modest, benefit in populations who are experiencing measurable stress, anxiety, or mood disruption — particularly those who may have suboptimal magnesium status at baseline.

---

Magnesium Evidence Analysis: Limitations and Research Gaps

Any honest magnesium evidence analysis must grapple with the significant methodological limitations in the current literature. These are not reasons to dismiss magnesium — they are reasons to calibrate your confidence in the conclusions appropriately.

Heterogeneity Across Trials

The most consistent challenge in the magnesium clinical evidence synthesis literature is high heterogeneity. Trials differ in the form of magnesium used, the dose, the duration, the population studied (healthy vs. clinically anxious vs. deficient), the outcome measures employed, and the co-interventions allowed. High heterogeneity produces wide confidence intervals in meta-analyses and reduces confidence in pooled estimates.

The 2025 systematic review and meta-analysis explicitly noted that effects on oxidative stress biomarkers other than CRP were inconclusive partly because of this heterogeneity problem. Future trials that pre-specify forms, doses, populations, and outcome measures in line with a common protocol would substantially improve the quality of evidence available.

Publication Bias

Like all supplement research, the magnesium anxiety meta-analysis literature is susceptible to publication bias — the tendency for positive trials to be published and negative trials to be filed away. Although modern registration requirements (e.g., ClinicalTrials.gov and PROSPERO pre-registration) are improving transparency, historical publication bias cannot be fully corrected in retrospective analyses.

Short Follow-Up Durations

Most trials in the magnesium evidence review literature run for eight to twelve weeks. This is sufficient to detect acute effects but insufficient to characterize long-term safety, whether benefits persist after discontinuation, or whether tolerance develops. For people managing chronic stress over months or years, these short-duration data provide limited guidance.

Lack of Standardized Magnesium Status Assessment

Perhaps the most important unresolved question in the magnesium clinical review field is whether baseline magnesium status moderates treatment response. Measuring magnesium status is technically difficult — serum magnesium is a poor indicator of total body stores — but without characterizing who is deficient versus replete at baseline, it is impossible to know whether the observed benefits represent a genuine pharmacological effect or simply the correction of a nutritional deficiency.

Regulatory and Placebo Challenges

Placebo-controlling magnesium trials is more difficult than it might appear. Some participants can distinguish magnesium from placebo by gastrointestinal sensations. The laxative effect of higher doses, in particular, can unblind participants. This introduces the possibility of expectancy effects inflating reported psychological outcomes.

---

Upcoming Magnesium Evidence Review: What the 2026 PROSPERO Protocol Plans to Answer

The most forward-looking development in the magnesium systematic review field is the 2026 PROSPERO-registered protocol (registration number CRD420261419777). PROSPERO is the international prospective register of systematic reviews, maintained by the Centre for Reviews and Dissemination at the University of York. Pre-registering a systematic review protocol on PROSPERO is considered a mark of methodological rigor because it commits researchers to their planned methods before they see the data.

What the 2026 Protocol Plans to Examine

The registered protocol for this upcoming magnesium systematic review and meta-analysis is designed to synthesize RCTs published between 2016 and 2025. Its central question is whether oral magnesium supplementation reduces stress scores in adults. Key features of the planned review include:

• Population: Adults with self-reported or clinically measured psychological distress, anxiety, depression, or stress
• Intervention: Oral magnesium supplementation in any form and dose
• Comparator: Placebo or active comparator
• Outcomes: Validated psychological distress scores (the primary outcome), as well as anxiety, depression, and stress subscale scores
• Study design: Randomized controlled trials only

By restricting the synthesis to RCTs from 2016 to 2025, the protocol aims to capture a more methodologically homogeneous body of evidence than previous reviews, which often included older studies with weaker designs. The restriction to oral supplementation also excludes intravenous magnesium studies, which are not relevant to consumer supplementation contexts.

Why This Matters

The 2026 PROSPERO protocol represents the most rigorously designed piece of upcoming magnesium evidence analysis work. When published, it is likely to provide the most reliable estimate yet of whether oral magnesium supplementation produces clinically meaningful reductions in psychological stress outcomes across a contemporary population of well-designed RCTs. It will also likely provide better data on dose-response relationships and moderating factors than any previous magnesium clinical review has been able to offer.

Readers who want the most current evidence synthesis on this topic should watch for the publication of this registered review, expected to synthesize data through 2025.

---

Practical Takeaways From the Magnesium Clinical Evidence Synthesis

With the full landscape of the magnesium meta-analysis stress research in view, here are the most defensible practical conclusions that the magnesium clinical evidence synthesis currently supports.

1. The Anti-Inflammatory Signal Is Consistent

The 2025 systematic review and meta-analysis found a statistically significant reduction in CRP across pooled studies. This is the most robust biomarker finding in the current magnesium evidence review, and it is clinically relevant because low-grade inflammation is increasingly recognized as a mediating factor in stress-related psychological symptoms. Magnesium's anti-inflammatory profile appears to be a real effect, not a statistical artifact.

2. Self-Reported Stress and Anxiety Scores Improve With Supplementation

Both the 2021 randomized trial and the 2020 review found meaningful reductions in validated psychological stress and anxiety scores following magnesium supplementation. The 2020 review reported DASS score reductions of up to 45% from baseline in high-stress participants. These are not trivial effect sizes, though they are most consistent in people with severe baseline stress and likely suboptimal magnesium status.

3. 300 mg Elemental Magnesium Per Day for at Least Four Weeks Is the Best-Supported Protocol

The most commonly studied dose in the magnesium anxiety pooled literature is approximately 300 mg elemental magnesium per day. Benefits appear to emerge within four weeks and stabilize by eight weeks. This is a practical, achievable, and broadly well-tolerated dose for most adults.

4. Severe Stress May Warrant Adding Vitamin B6

For people with severe baseline stress scores, the evidence from the 2021 trial suggests that combining magnesium with vitamin B6 (30 mg per day) may provide additional benefit over magnesium alone. For people with moderate or mild stress, magnesium alone appears sufficient to produce meaningful improvement.

5. Form Matters for Bioavailability

The magnesium evidence analysis literature does not yet provide a definitive head-to-head comparison of forms for stress outcomes, but general pharmacokinetic data favor more bioavailable forms (magnesium glycinate, citrate, or threonate) over magnesium oxide. Choosing a form with established bioavailability is a reasonable practical decision given the current evidence gaps.

6. Safety Profile Is Favorable at Standard Doses

Magnesium supplementation at doses of 300 mg to 400 mg elemental magnesium per day has a well-established safety profile in adults without kidney disease. The primary side effect is gastrointestinal discomfort or loose stools, which is more common at higher doses and with less bioavailable forms. People with kidney disease or those taking certain medications (including some diuretics, antibiotics, and proton pump inhibitors) should consult a healthcare provider before supplementing.

7. The Evidence Is Encouraging but Not Definitive

Honest engagement with the magnesium clinical review literature requires acknowledging that the evidence base, while promising, is not yet strong enough to issue unqualified clinical recommendations. The heterogeneity problem, the likely influence of baseline magnesium status, and the absence of long-term data all limit confidence. The 2026 PROSPERO-registered meta-analysis is likely to substantially clarify the picture when published.

---

Frequently Asked Questions

Does magnesium help reduce stress?

Based on the current magnesium stress meta and systematic review literature, the answer is a qualified yes. Multiple trials using validated psychological instruments such as the DASS-42 have found significant reductions in stress scores following magnesium supplementation. A 2020 review found that magnesium intake was negatively correlated with stress and DASS scores, and a 2021 randomized trial found improvements to near-normal levels after eight weeks in stressed healthy adults. The effect appears most consistent in people with severe baseline stress and likely suboptimal magnesium intake.

Which form of magnesium is best for stress?

The magnesium anxiety pooled data literature does not yet offer a definitive head-to-head comparison. However, general bioavailability data favor magnesium glycinate, citrate, and threonate over magnesium oxide. Most trials in the magnesium clinical evidence synthesis literature that reported positive stress outcomes used forms with reasonable bioavailability, suggesting that form selection may matter for achieving sufficient tissue levels.

How long does magnesium take to work for stress symptoms?

The 2021 randomized trial found that the greatest change in DASS-42 stress and anxiety scores occurred in the first four weeks, with near-normal values achieved by week eight. The magnesium stress meta literature is broadly consistent with this timeline. Individuals expecting immediate results within one to two weeks may underestimate the required duration.

Is magnesium more effective alone or with vitamin B6?

For people with moderate stress, the magnesium evidence analysis literature suggests that magnesium alone produces meaningful improvement. For people with severe baseline stress, the 2021 trial's secondary analysis found that magnesium combined with vitamin B6 (30 mg/day) produced significantly greater improvement than magnesium alone. The combination may therefore be worth considering in high-stress contexts.

What dose of magnesium is used in stress studies?

The most common dose in the magnesium clinical review literature is approximately 300 mg elemental magnesium per day. The 2020 review specifically studied 300 mg with or without vitamin B6 and found significant stress-relief benefits. Most trials fall in the range of 200 mg to 400 mg elemental magnesium per day.

Are there side effects or risks from magnesium supplementation?

At supplemental doses of 300 mg to 400 mg elemental magnesium per day, the risk profile is generally favorable for healthy adults. The most common side effect is gastrointestinal discomfort — loose stools or diarrhea — which is more likely at higher doses and with poorly absorbed forms such as magnesium oxide. Individuals with impaired kidney function should not supplement without medical guidance, as the kidneys regulate magnesium excretion and impaired clearance can lead to hypermagnesemia.

Does magnesium help stress, anxiety, or sleep most reliably?

Based on the current magnesium mental health review and magnesium anxiety meta-analysis literature, the strongest evidence is for self-reported psychological stress and anxiety scores measured by validated instruments. Sleep improvement is commonly reported as a secondary benefit in stress trials. The evidence for magnesium specifically as a standalone sleep intervention is weaker than the stress and anxiety evidence stream.

Is the evidence strong enough to recommend magnesium for stress?

The magnesium evidence review literature provides encouraging but not yet definitive evidence. The anti-inflammatory signal (CRP reduction) from the 2025 systematic review is robust. The psychological outcome data from multiple trials are promising, particularly in high-stress populations. However, methodological heterogeneity, the likely influence of baseline deficiency, and the absence of long-term data all mean that qualified clinical recommendations await more definitive evidence — which the 2026 PROSPERO-registered meta-analysis may help provide.

---

Summary

The magnesium meta-analysis stress research landscape in 2025 and 2026 offers a more nuanced picture than either enthusiastic supplement advocates or dismissive critics typically present. The most rigorous current evidence — a 2025 systematic review and meta-analysis of 28 studies — found a significant and consistent reduction in CRP, a meaningful inflammatory biomarker, but inconclusive effects on other oxidative stress biomarkers. Randomized controlled trial data from 2021 and a 2020 review show clinically meaningful reductions in validated psychological stress and anxiety scores at 300 mg magnesium per day over four to eight weeks, particularly in people with severe baseline stress.

The magnesium clinical evidence synthesis field is actively evolving. A 2026 PROSPERO-registered systematic review and meta-analysis is designed to produce the most comprehensive and methodologically rigorous pooled estimate yet of magnesium's effects on psychological stress outcomes. Until those results are available, the current magnesium evidence review supports cautious optimism — magnesium supplementation at standard doses is safe, has a plausible biological rationale, produces consistent anti-inflammatory effects, and generates meaningful improvements in validated stress and anxiety scores in well-conducted trials.

What it does not yet support is certainty. The evidence is promising, not proven. And that honest assessment is, ultimately, what the magnesium clinical review literature itself tells us.

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any supplementation protocol, particularly if you have existing medical conditions or take prescription medications.

---

References

1. Systematic review and meta-analysis (2025): Magnesium supplementation and oxidative stress biomarkers, 28 articles reviewed (2000–2025); significant CRP reduction found; effects on NO, TAC, MDA, and GSH inconclusive.
2. PROSPERO registration CRD420261419777 (2026): Planned systematic review and meta-analysis of oral magnesium supplementation for psychological stress outcomes in adults; RCTs 2016–2025.
3. Consumer health coverage (2026): Multiple commercial-content sources discuss magnesium for brain health and stress; these are not primary clinical studies.
4. Randomized controlled trial with secondary analysis (2021): Magnesium with or without vitamin B6 in stressed healthy adults; DASS-42 scores improved to normal or near-normal by week 8; greatest change in first 4 weeks.
5. Review (2020): 300 mg magnesium daily, with or without 30 mg vitamin B6; DASS score reductions up to 45% from baseline in severe-stress participants; magnesium intake negatively correlated with total DASS, stress, and depression scores.